Literature DB >> 34043183

Quantitative proteomics revealed the molecular characteristics of distinct types of granulated somatotroph adenomas.

Yifan Tang1, Tao Xie1, Silin Wu1, Qiaoqiao Yang2, Tengfei Liu1, Chen Li1, Shuang Liu1, Zhiyong Shao1,3, Xiaobiao Zhang4,5,6.   

Abstract

PURPOSE: Somatotroph adenomas are obviously heterogeneous in clinical characteristics, imaging performance, pathological diagnosis and therapeutic effect. The heterogeneity of the tumors, especially for SG and DG type adenomas, have attracted great interest in identifying the specific pathological markers and therapeutic targets of them. However, previous analyses of the molecular characteristics of the subtypes of somatotroph adenomas were performed at genomic and transcriptome level. The proteomic differences between the two subtypes of somatotroph adenomas are still unknown.
METHODS: Tumor samples were surgically removed from 10 sporadic pituitary somatotroph adenoma patients and grouped according to the pathological type. Tandem mass tag (TMT)-based quantitative proteomic analysis was employed to analyze the proteomic differences between SG and DG tumors.
RESULTS: In total, 228 differentially expressed proteins were identified between SG adenomas and DG adenomas. They were enriched mainly in extracellular matrix (ECM)-receptor interaction, leukocyte transendothelial migration, arrhythmogenic right ventricular cardiomyopathy and DNA replication pathways. Protein-protein interaction (PPI) network analysis indicated that Cadherin-1 and Catenin beta-1 were the most important key proteins in the differences between SG and DG adenomas. Immunohistochemistry (IHC) confirmed the expression levels of the key proteins.
CONCLUSIONS: This study provides large-scale proteome molecular characteristics of distinct granulation subtypes of somatotroph adenomas. Compared with DG adenomas, The differential protein of SG adenomas mostly enrich in invasive and proliferative functions and pathways at the proteomic level. Cadherin-1 and Catenin beta-1 play key roles in the different biological characteristics of the two tumor subtypes.

Entities:  

Keywords:  Acromegaly; GH; Molecular network; Pituitary adenoma; Quantitative proteomics; Tandem mass tag (TMT)

Year:  2021        PMID: 34043183     DOI: 10.1007/s12020-021-02767-1

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  50 in total

Review 1.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 2.  Acromegaly.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

Review 3.  The pathogenesis of pituitary tumors.

Authors:  Sylvia L Asa; Shereen Ezzat
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

Review 4.  60 YEARS OF NEUROENDOCRINOLOGY: Acromegaly.

Authors:  Cristina Capatina; John A H Wass
Journal:  J Endocrinol       Date:  2015-07-01       Impact factor: 4.286

5.  Growth hormone tumor histological subtypes predict response to surgical and medical therapy.

Authors:  Katja Kiseljak-Vassiliades; Nichole E Carlson; Manuel T Borges; B K Kleinschmidt-DeMasters; Kevin O Lillehei; Janice M Kerr; Margaret E Wierman
Journal:  Endocrine       Date:  2014-08-17       Impact factor: 3.633

6.  T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.

Authors:  Iulia Potorac; Patrick Petrossians; Adrian F Daly; Orsalia Alexopoulou; Sophie Borot; Mona Sahnoun-Fathallah; Frederic Castinetti; France Devuyst; Marie-Lise Jaffrain-Rea; Claire Briet; Florina Luca; Marion Lapoirie; Flavius Zoicas; Isabelle Simoneau; Alpha M Diallo; Ammar Muhammad; Fahrettin Kelestimur; Elena Nazzari; Rogelio Garcia Centeno; Susan M Webb; Marie-Laure Nunes; Vaclav Hana; Véronique Pascal-Vigneron; Irena Ilovayskaya; Farida Nasybullina; Samia Achir; Diego Ferone; Sebastian J C M M Neggers; Brigitte Delemer; Jean-Michel Petit; Christof Schöfl; Gerald Raverot; Bernard Goichot; Patrice Rodien; Bernard Corvilain; Thierry Brue; Franck Schillo; Luaba Tshibanda; Dominique Maiter; Jean-François Bonneville; Albert Beckers
Journal:  Endocr Relat Cancer       Date:  2016-09-20       Impact factor: 5.678

7.  Pituitary acromegaly: not one disease.

Authors:  Sylvia L Asa; Walter Kucharczyk; Shereen Ezzat
Journal:  Endocr Relat Cancer       Date:  2017-01-25       Impact factor: 5.678

Review 8.  Acromegaly pathogenesis and treatment.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

9.  Mortality in acromegaly: a metaanalysis.

Authors:  O M Dekkers; N R Biermasz; A M Pereira; J A Romijn; J P Vandenbroucke
Journal:  J Clin Endocrinol Metab       Date:  2007-10-30       Impact factor: 5.958

10.  Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas.

Authors:  Bernhard Mayr; Rolf Buslei; Marily Theodoropoulou; Günter K Stalla; Michael Buchfelder; Christof Schöfl
Journal:  Eur J Endocrinol       Date:  2013-09-12       Impact factor: 6.664

View more
  1 in total

1.  Predicting Subtype of Growth Hormone Pituitary Adenoma based on Magnetic Resonance Imaging Characteristics.

Authors:  Chen-Xi Liu; Sheng-Zhong Wang; Li-Jun Heng; Yu Han; Yu-Hui Ma; Lin-Feng Yan; Ying Yu; Wen Wang; Yu-Chuan Hu; Guang-Bin Cui
Journal:  J Comput Assist Tomogr       Date:  2022 Jan-Feb 01       Impact factor: 1.826

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.